@article{23572a7d218347de8f4fba6a7be9ceff,
title = "Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer",
keywords = "Angiogenesis, Monoclonal antibody, Vascular endothelial growth factor",
author = "Bhuvaneswari Ramaswamy and Shapiro, \{Charles L.\}",
note = "Funding Information: A phase II trial of bevacizumab in combination with docetaxel, sponsored by the Cancer and Treatment Evaluation Program of the National Cancer Institute, has been initiated at our institution. The objectives and eligibility criteria for the trial are outlined in Tables 1 and 2. Surrogate markers for angiogenesis, including vascular cell adhesion molecule–1,25E-selectin, and others (Table 1) will be analyzed in all patients before and after 1 cycle of treatment and within 2 weeks of disease progression. In patients with tumors amenable to sequential biopsies, mi-crovessel density and apoptotic indices will be evaluated.",
year = "2003",
month = oct,
doi = "10.3816/CBC.2003.n.035",
language = "English",
volume = "4",
pages = "292--294",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
number = "4",
}